These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 35441412)

  • 1. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
    Davies MJ; Rosenstock J; Ali A; Russell-Jones D; Souhami E; Palmer K; Ji C; Niemoeller E; Skolnik N
    Diabetes Obes Metab; 2022 Jan; 24(1):34-41. PubMed ID: 34617398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
    Yang W; Guo X; Lauand F; Li L; Fang H; Du Q; Kang L
    Diabetes Obes Metab; 2024 Apr; 26(4):1197-1206. PubMed ID: 38172083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
    Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
    Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
    Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
    Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
    Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
    Watada H; Takami A; Spranger R; Amano A; Hashimoto Y; Niemoeller E
    Diabetes Care; 2020 Jun; 43(6):1249-1257. PubMed ID: 32295808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
    Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
    Guo X; Yang W; Zhang J; Dong X; Liu M; Gu S; Lauand F; Li L; Huang Q; Kang L; Souhami E
    Diabetes Obes Metab; 2023 Jul; 25(7):2005-2011. PubMed ID: 36999231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
    Kaneto H; Takami A; Spranger R; Amano A; Watanabe D; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
    Davies MJ; Russell-Jones D; Barber TM; Lavalle-González FJ; Galstyan GR; Zhu D; Baxter M; Dessapt-Baradez C; McCrimmon RJ
    Diabetes Obes Metab; 2019 Aug; 21(8):1967-1972. PubMed ID: 31124299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
    Wysham C; Bonadonna RC; Aroda VR; Puig Domingo M; Kapitza C; Stager W; Yu C; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Obes Metab; 2017 Oct; 19(10):1408-1415. PubMed ID: 28386990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M; Gu W; Chen L; Li Y; Kuang H; Du J; Alvarez A; Lauand F; Souhami E; Zhang J; Xu W; Du Q; Mu Y;
    Diabetes Obes Metab; 2024 Sep; 26(9):3791-3800. PubMed ID: 38922731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
    Frias J; Puig Domingo M; Meneghini L; Napoli R; Liu M; Soltes Rak E; Aroda VR
    Diabetes Obes Metab; 2018 Sep; 20(9):2314-2318. PubMed ID: 29785837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
    Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
    Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
    Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.